Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05973084 · ClinicalTrials.gov registry record
COVID-19 Transmission and Morbidity in Malawi
A clinical trial of SARS CoV 2 Infection and SARS CoV 2 Vaccination, sponsored by Boston University.
- Recruiting
- Registry status
- 1,500
- Enrollment target
- 2
- Study locations
NCT05973084: Recruiting study of SARS CoV 2 Infection and SARS CoV 2 Vaccination, sponsored by Boston University.
NCT05973084 is a study of SARS CoV 2 Infection and SARS CoV 2 Vaccination that is actively recruiting participants, run by Boston University. The registered enrollment target is 1,500 participants, below the 4,145-participant average among 35 other SARS CoV 2 Infection trials with a reported enrollment target (64% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05973084, a study of SARS CoV 2 Infection and SARS CoV 2 Vaccination, is actively recruiting participants, sponsored by Boston University.
- RECRUITING
- Registry status
- 1,500 participants
- Enrollment target
- 2
- Study locations
Study Summary
SARS-CoV-2 transmission was expected to have a devastating impact in sub-Saharan African countries. Instead, morbidity and mortality rates in nearly the whole region are an order of magnitude lower than in Europe and the Americas. To identify what is different requires a better understanding of the underlying immunological substrate of the population, and how these factors affect susceptibility to infection, progression of symptoms, transmission, and responses to SARS-CoV-2 vaccination. Study objectives 1. Determine the risk and predictors of infection and disease among contacts of SARS-CoV-2 infection subjects in Malawi 2. Determine whether innate immune responses lower the risk of SARS-CoV-2 infection and disease, and acquisition and duration of vaccine responses. 3. Assess whether alterations in innate immune responses relevant to SARS-CoV-2 are associated with malaria or intestinal parasite infections. 4. Assess the acquisition and longevity of antibodies (Ab) and cellular adaptive responses elicited by SARS-CoV-2 infection and vaccination. 5. Assess whether malaria and intestinal parasite infections, chronic/mild undernutrition, and anemia mediate alterations in Ab and other adaptive cellular responses to SARS-CoV-2 through innate immune responses or a different unknown mechanism.
Primary Outcome
Proportion of household members who acquire an asymptomatic (vs. symptomatic) infection among household contacts of an index case
Conditions Studied
Study Locations (2)
Massachusetts
- BU School of Public Health, Global Health Department - Boston
Other
- Health center - Blantyre
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,500 participants |
| Start Date | 2023-01-17 |
| Est. Completion | 2028-03 |
What NCT05973084 shows while recruiting
NCT05973084 is an observational study that tracks outcomes without assigning an intervention. Its 1,500 participants enrollment target places it among the larger protocols in the corpus, below the 4,145-participant average among 35 other SARS CoV 2 Infection trials with a reported enrollment target (64% lower).
The record links to 2 conditions, with SARS CoV 2 Infection appearing as the primary indexed condition, and to 0 interventions.
NCT05973084 reports a single indexed study location in Massachusetts, Other.
Frequently Asked Questions
What is clinical trial NCT05973084 about?
NCT05973084 is a clinical study titled "COVID-19 Transmission and Morbidity in Malawi". SARS-CoV-2 transmission was expected to have a devastating impact in sub-Saharan African countries. Instead, morbidity and mortality rates in nearly the whole region are an order of magnitude lower than in Europe and the Americas. To identify what is different requires a better understanding of the ...
What is the current status of trial NCT05973084?
This trial is currently recruiting. The enrollment target is 1,500 participants. The study started on 2023-01-17. Estimated completion is 2028-03.
What conditions does trial NCT05973084 study?
This clinical trial studies the following conditions: SARS CoV 2 Infection, SARS CoV 2 Vaccination.
Who is sponsoring clinical trial NCT05973084?
This trial is sponsored by Boston University, which has 185 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05973084 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for SARS CoV 2 Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05973084's enrollment target sits among peer trials
1,500 7th of 35 higher than 29 of 35 other SARS CoV 2 Infection trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other SARS CoV 2 Infection trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Exercise in Child Health
RECRUITING · NA
-
NIH RECOVER Tissue Pathology: Understanding the Long-Term Impact of COVID-19
RECRUITING
-
Cardiovascular Autonomic and Immune Mechanism of Post COVID-19 Tachycardia Syndrome
RECRUITING · NA
-
Effect of 2-HOBA in Persistent Immune Activation in Long COVID POTS
RECRUITING · Phase 2
-
CU-COMMITS: COVID-19 Care in Black and Latino Communities and Households. Clinical and Molecular Outcomes of SARS-CoV-2
RECRUITING
-
Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00178724 · 1,500 participants
Spinal Cord Injury Registry - North American Clinical Trials Network
- NCT00951366 · 1,500 participants
Preterm Lung Patient Registry
- NCT01050504 · 1,500 participants
Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer
- NCT02071134 · 1,500 participants
Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI